DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20201185

An experimental study to evaluate the role of aspirin and metformin in prevention of depression in rats

Alisha Abbas, Narendra Kumar, Sarvesh Singh, Rahul Kumar, Akhlaque Ahmad, Rajendra Nath, Rakesh Kumar Dixit

Abstract


Background: Depression was seen to be associated with an increased level of inflammatory biomarkers along with the disturbance in the monoamine neurotransmitter system. Current therapies are mostly focussed on the neurotransmitters imbalance but due to increasing cases of treatment failure there is a need to shift our treatment focus to other potential therapies. This study aimed to evaluate the preventive role of aspirin and metformin in stress induced model of depression in wistar rats.

Methods: Fifty four wistar rats were randomly divided into nine groups as normal control, experimental control, aspirin (30 mg/kg, 60 mg/kg), metformin (50 mg/kg, 100 mg/kg), two combination groups and imipramine (15 mg/kg). Depression model was created by the induction of chronic unpredictable mild stress (CUMS) for consecutive 28 days. Behavioural assessment was done by evaluating immobility time in forced swim test (FST) and sucrose preference ratio (SPR) in sucrose preference test. The data were analysed by analysis of variance (ANOVA) test using SPSS software. P<0.05 was considered to be statistically significant.

Results: The CUMS led to an increase in immobility time and decrease in SPR. Aspirin and Metformin alone and their combinations showed statistically significant response in preventing the immobility time to increase (p<0.001) and SPR to decrease (p<0.001). However the response of Aspirin was comparable with Imipramine but the response of Metformin was not as significant as of Imipramine (p>0.05).

Conclusions: Aspirin and metformin might have a potential role in the prevention of depression.


Keywords


Aspirin, Chronic unpredictable mild stress, Depression, Inflammation, Metformin

Full Text:

PDF

References


Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatr. 2003;64(12):1465-75.

Holsboer F, Doerr HG, Gerken A, Müller OA, Sippell WG. Cortisol, 11-deoxycortisol and ACTH concentrations after dexamethasone in depressed patients and healthy volunteers. Psychiatr Res. 1984;11(1):15-23.

Maes M. The serotonin hypothesis of depression. Psychopharmacology: the fourth generation of progress. 1995:933-44.

Kohler O, Krogh J, Mors O, Benros EM. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14(7):732-42.

Hughes MM, Connor TJ, Harkin A. Stress-related immune markers in depression: implications for treatment. Int J Neuropsychopharmacol. 2016;19(6):1-19.

Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opinion Investigat Drugs. 2009;10(7):664.

Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, et al. Regulation of the human serotonin transporter by interleukin-1β. Biochem Biophys Res Commun. 1995;216(2):560-7.

Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, et al. Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis. Translat Psychiatr. 2017;7(5):1138.

Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmacol. 2012;62(1):419-26.

Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46.

Grosser T, Smythe E, FitzGerald GA. Goodman & Gilman’s The pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill publishers; 2011.

Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261.

Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to β-amyloid. Aging. 2009;1(2):234.

Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with Metformin use in subjects with type 2 diabetes. Diabetes Med. 2005;22(4):497-502.

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5.

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860.

Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J, et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PloS One. 2014;9(3):e91111.

Grippo AJ, Moffitt JA, Johnson AK. Cardiovascular alterations and autonomic imbalance in an experimental model of depression. Am J Physiol Regul Integr Comp Physiol. 2002;282(5):1333-41.

Tang M, Jiang P, Li H, Cai H, Liu Y, Gong H, et al. Antidepressant-like effect of n-3 PUFAs in CUMS rats: role of tPA/PAI-1 system. Physiol Behav. 2015;139:210-5.

Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacol. 1987;93(3):358-64.

Fekadu N, Shibeshi W, Engidawork E. Major depressive disorder: pathophysiology and clinical management. J Depress Anxiety. 2017;6:255-7.

Bhatt S, Shukla P, Raval J, Goswami S. Role of Aspirin and dexamethasone against experimentally induced depression in rats. Basic Clin Pharmacol Toxicol. 2016;119(1):10-8.

Liu MY, Yin CY, Zhu LJ, Zhu XH, Xu C, Luo CX, et al. Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc. 2018;13(7):1686.

Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatr. 2007;13(7):717-28.

Kitamura Y, Fujitani Y, Kitagawa K, Miyazaki T, Sagara H, Kawasaki H, et al. Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biol Pharm Bull. 2008;31(2):246-9.

Shivavedi N, Kumar M, Tej GN, Nayak PK. Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats. Brain Res. 2017;1674:1-9.

Keshavarzi S, Kermanshahi S, Karami L, Motaghinejad M, Motevalian M, Sadr S. Protective role of Metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: the role of CREB/BDNF and Akt/GSK3 signaling pathways. Neurotoxicol. 2019;72:74-84.